Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roivant Sciences Ltd (NQ: ROIV ) 10.80 +0.12 (+1.08%) Streaming Delayed Price Updated: 11:36 AM EDT, Jun 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roivant Sciences Ltd < Previous 1 2 3 4 5 6 7 Next > Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update June 28, 2023 From Roivant Sciences Via GlobeNewswire Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023 June 26, 2023 From Roivant Sciences Via GlobeNewswire Why Roivant Sciences Stock Is Perking Up Today June 22, 2023 Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock. Via The Motley Fool Why Roivant Sciences Stock is Trading Higher Today June 22, 2023 Roivant Sciences Ltd (NASDAQ: ROIV) released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with Via Benzinga A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout June 22, 2023 The company is testing a treatment that blocks an inflammatory ligand in patients with ulcerative colitis. Via Investor's Business Daily 5 Analysts Have This to Say About Roivant Sciences June 08, 2023 Via Benzinga Why Shares of Roivant Sciences Jumped This Week April 20, 2023 The company's stock benefited from another company's buyout. Via The Motley Fool Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 22, 2023 Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... Via Benzinga Steelcase, Commercial Metals And Other Big Stocks Moving Higher On Thursday June 22, 2023 U.S. stocks traded mixed, with the Dow Jones dropping around 50 points on Thursday. Here are some big stocks recording gains in today’s session. Via Benzinga Analyst Expectations for Roivant Sciences's Future March 16, 2023 Via Benzinga Roivant Sciences Highlights Topline Data From Atopic Dermatitis Drug In Patients As Young As 2 Years March 15, 2023 Via Benzinga Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period June 22, 2023 From Roivant Sciences Via GlobeNewswire Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis June 21, 2023 From Roivant Sciences Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2023 June 08, 2023 Via Benzinga The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree June 02, 2023 Big Pharma is facing a patent cliff that could siphon off billions in revenue. Via Investor's Business Daily Marching Towards FDA Approval: Dermavant's Vtama Cream Excels in Phase 3 Trial, Eyes 2024 Submission May 16, 2023 Dermavant Sciences, a Roivant Sciences (NASDAQ: ROIV) company, announced results from ADORING 1 Phase 3 trial of topical Vtama (tapinarof) cream, 1% in adults and pediatric subjects down to 2 years old... Via Benzinga Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old May 16, 2023 From Roivant Sciences Via GlobeNewswire Why Did Pfizer Offload This Potential Mega-Blockbuster Drug? April 23, 2023 Pfizer's decision to offload a potential mega-blockbuster may seem counterintuitive, but the drugmaker appears to have solid reasons for doing so. Via The Motley Fool These 2 Growth Stocks Might Be Incredibly Undervalued Right Now April 20, 2023 These two biopharma stocks could be poised for a major growth spurt. Via The Motley Fool EXCLUSIVE: Joe Biden Tops 2024 Election Betting Odds, How Negative Headlines And Indictment Move Trump Ahead Of DeSantis April 17, 2023 While the 2024 U.S. presidential election may seem a long way off, polls to see who is favored by voters and betting odds for the next White House occupant have ramped up. Via Benzinga These 3 Nasdaq Stocks Are on Fire Today: Here's Why April 17, 2023 A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. Via The Motley Fool Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom April 17, 2023 Merck is branching into immune-mediated diseases with this takeover. Via Investor's Business Daily Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session April 17, 2023 U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93... Via Benzinga Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory April 04, 2023 From Lokavant Via Business Wire Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research April 04, 2023 From Lokavant Via Business Wire 7 Biotech Stocks to Buy for Breakthrough Treatments and Cures March 29, 2023 For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. Via InvestorPlace Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients March 28, 2023 From Covant Therapeutics Via GlobeNewswire Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 21, 2023 Gainers U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share. Via Benzinga Why Shares of Roivant Sciences Were Down Tuesday March 21, 2023 After a run-up last week prompted by positive clinical trial results, the stock has given back its recent gains. Via The Motley Fool The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector March 15, 2023 To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. Via InvestorPlace < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.